Hologic to showcase portfolio of comprehensive breast and skeletal health solutions at RSNA 2022

new Affirm® Contrast Biopsy Technique Involved in Screening, Diagnosis, Treatment and performance monitoring solutions

Marlboro, Mass., November 25, 2022–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX) will showcase its broad portfolio of breast and skeletal health products at the 108th Conference.th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 27 to December 1. Hologics Firm in Full Suite of Breast Biopsy and Surgery Solutions Contrast biopsy software, which will be on display for the first time since it became commercially available in the United States.

“As the global leader in breast imaging, we are committed to meeting the unmet needs of physicians and their patients across the continuum of breast care and we look forward to joining industry leaders at this year’s RSNA meeting to share our vision for the future.” About breast health,” said Eric Anderson, President, Hologics Breast & Skeletal Health Solutions Division. “We are equally excited to showcase our new Affirm Contrast Biopsy technology, which is a great example of our commitment to physicians and patients alike.”

Confirm Contrast Biopsy software allows physicians to target and obtain tissue samples in lesions identified with i-View Contrast-enhanced mammography software. Contrast solution provides healthcare facilities with a viable and attractive alternative to breast MRI, which has historically been used to find and biopsy more elusive lesions, such as those that cannot be seen through mammography or ultrasound Is. While breast MRI can be time consuming and expensive, contrast technology gives radiologists another option in the mammography suite that overcomes these drawbacks.1,2 In a recent clinical study, 98% of patients had an overall positive opinion about their procedure experience with Confirm Contrast Biopsy Software.3

RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South Hall Level 3 of McCormick Place in Chicago. In addition to Affirm Contrast Biopsy software, Hologic will feature its Dimensions mammography portfolio and the Supersonic® MACH™ ultrasound system.

Hologic will also host a range of CME- and non-CME-accredited medical education symposia and learning opportunities, accessible to attendees on-site and from remote locations. Medical education sessions include:

  • “Upright Biopsy with the Bravera® Breast Biopsy System: Real-Time Imaging, Verification and Automated Handling”
    Sunday, November 27: 11:45 AM – 12:45 PM CST
    Dr. Krystal Arola will demonstrate new upright breast biopsy techniques that will enhance accuracy, workflow, and patient experience. She will share her experiences with the Affirm 2D/3D Upright Biopsy, the Lateral Arm Approach, and the Bravera Breast Biopsy System, which integrates tissue acquisition, real-time imaging and verification, and post-biopsy sample handling. Dr. Airola will also share cases and explain how to minimize time and discomfort for patients in the biopsy suite while maximizing the efficiency of the biopsy suite and clinical decision making.

  • “Emerging Ultrasound Techniques in Liver Surveillance”
    Monday, November 28: 12:00 noon – 1:00 pm CST
    Learn more about advances in ultrasound technology with ShearWave™ Elastography. There are many opportunities to improve workflow efficiency in liver surveillance that provide better patient experience and outcomes. In this lecture, participants will review existing and emerging ultrasound techniques and comparisons with techniques.

  • “Current AI Applications in Mammography: Focus on Genius AI™ Detection Software”
    Tuesday, November 29: 12:00 noon – 1:00 pm CST
    Attendees will hear from an expert about the benefits of artificial intelligence (AI) in mammography screening. As new high-resolution techniques are implemented, see how AI can reduce dosage, file size and read time. The focus will be on the benefits of deep-learning AI and Genius AI detection software in driving clinical decision making and increasing productivity.

  • “Panel Discussion: Choices in Localization”
    Wednesday, November 30: 12:00 noon – 1:00 pm CST
    Join a multidisciplinary conversation on localization. Hear from leading radiologists and breast surgeons’ perspectives on what they like, what they use and why. What is the role of stars? What other technologies are available? What are the strengths and weaknesses of the different options?

Hologic, Inc. about
Hologic, Inc. is a global medical technology innovator primarily focused on improving the health and well-being of women through early detection and treatment. Its advances include the invention of the world’s first commercial 3D Mammography™ system to fight breast cancer; leadership in testing for cervical cancer, sexually transmitted infections, respiratory diseases, and the virus that causes COVID-19; and minimally invasive surgical techniques for uterine fibroids and abnormal uterine bleeding.

The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which provides awareness, research insights, and opportunities for underserved women. Increases access to quality care. hologic.com

Hologic, 3D Mammography, 3Dimensions, Affirm, Brevera, Dimensions, Genius AI, I-View, Mach, Selenia, ShearWave, Supersonic, and The Science of Sure, Hologic, Inc. are trademarks and/or registered trademarks of, and/or its subsidiaries in the United States and/or other countries.

forward-looking statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements regarding the use of Hologic products. There can be no assurance that these products will achieve the benefits described herein or that such benefits will be replicated in any particular way with respect to any individual patient, as the actual effectiveness of the use of the products will only be determined on a case-by-case basis. can be done. Case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected sales levels. Hologic expressly disclaims any obligation or undertaking to publicly release updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances. disclaims upon which any such data or statement is based.

This information is not intended as a solicitation or promotion of any product where such activities are prohibited. For specific information about which products are available for sale in a particular country, please contact a local Hologic sales representative or write to [email protected]

,

1

Publications for reference: Kaur, Piccolo, Arasaratnam. Implementation of Contrast-Enhanced Mammography in Clinical Practice, Chapter 7, Nori, Kaur (Eds.).), Contrast-enhanced digital mammography (CEDM). Springer, 2018.

2

Hobbs MM, Taylor DB, Buzinski S, Peek RE. Contrast-enhanced spectral mammography (CESM) and contrast MRI (CEMRI): patient preferences and tolerability. Journal of Medical Imaging and Radiation Oncology. 2015;59:300-305.

3

Holologic Clinical Study CSR-00266 Rev 001 2022

Source: Hologic, Inc.

View the source version on Businesswire.com: https://www.businesswire.com/news/home/20221125005011/en/

Contact

media Contact:
jane mazur
Vice President, Corporate Communications
(+1) 508.263.8764
[email protected]

Investor Contact:
Ryan Simon
Vice President, Investor Relations
(+1) 858.410.8514
[email protected]

Leave a Comment